Cyclosporine non-modified (Sandimmune)
Class/mechanism: Cyclic polypeptide immunosuppressive agent that reversibly and preferentially inhibits T-lymphocytes, especially the T-helper cell. Exact mechanism unknown. Suppresses humoral immunity and cell-mediated immune reactions, including graft vs. host disease, allograft rejection, delayed hypersensitivity, experimental allergic encephalomyelitis, and Freund’s adjuvant arthritis.
Route: IV, PO
Extravasation: no information
- Sandimmune IV injection is administered at 1/3 the PO (oral) dose of Sandimmune soft gelatin capsules or oral solution. (Cyclosporine non-modified (Sandimmune) package insert PDF page 18)
- Cyclosporine modified (Neoral/Gengraf) has higher bioavailability than Sandimmune, and particularly close attention should be given to monitoring of dose levels when changing between Neoral/Gengraf and Sandimmune.
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it is used
Patient drug information
Also known as
- Generic names: ciclosporin, CsA, CyA, cyclosporin, cyclosporin A
- Brand name: Sandimmune